[HTML] sciencedirect.com

[HTML][HTML] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer …

ACZ Gelatti, A Drilon, FC Santini - Lung cancer, 2019 - Elsevier
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
被引用次数：194 相关文章

[引用][C] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

ACZ Gelatti, A Drilon, FC Santini - Lung Cancer, 2019 - cir.nii.ac.jp
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor
receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) | CiNii Research CiNii …

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

ACZ Gelatti, A Drilon, FC Santini - Lung Cancer (Amsterdam …, 2019 - europepmc.org
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

ACZ Gelatti, A Drilon, FC Santini - Lung cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80-85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

ACZ Gelatti, A Drilon, FC Santini - Lung Cancer, 2019 - lungcancerjournal.info
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
[HTML] nih.gov

[HTML][HTML] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer …

A Gelatti, A Drilon, FC Santini - Lung cancer (Amsterdam …, 2019 - ncbi.nlm.nih.gov
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
[PDF] kimia-pharma.co

[PDF][PDF] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

ACZ Gelatti, A Drilon, FC Santini - Lung Cancer, 2019 - kimia-pharma.co
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

A Gelatti, A Drilon, FC Santini - lungcancerjournal.info
Review Article Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal
growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) Ana …

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

ACZ Gelatti, A Drilon, FC Santini - Lung Cancer (Amsterdam …, 2019 - europepmc.org
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …